

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DC 20231

Ł	APPLICATION NO. FILING DATE	FIRST NAMED	INVENTOR		ATTORNEY DOCKET NO.
	03701797	ADAIR		J	CARP-0057
		HM21/0701	_		
Г	FRANCIS A PAINTIN		EXAMINER		
				REEVES	i., J
	WOODCOCK WASHBURN KURTZ MACKIEWICZ AND NORRIS		_		
		FLOOR	[ART UNIT	PAPER NUMBER
	ONE LIBERTY PLACE 46TH PHILADELPHIA PA 19103	FLUUR	_	1642	•
			(DATE MAILED:	07/01/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

I



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
SCHIAL NOMBER	TILING DATE		
			<u> </u>

EXAMINER

ART UNIT PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The reply filed 6/9/98 as paper no 8, is not fully responsive to the communication mailed 4/28/98 for the reason(s) set forth below:

Sequences present on page 30, and 33 do not have SEQ ID Nos. The sequences on page 33 do not appear to be listed in the sequence listing. The amendments on pages 23-24. 38-40, 45, 50, 53 and 55 (received 20 March 1998) have not been entered because the coresponding text was not found on those pages. The specification has notbeen amended to recite the correct SEQ ID NOs.

- 2. Since the above-mentioned reply appears to be bona fide, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).
- 3. Any inquiry concerning this communication should be directed to Examiner Julie E. Reeves, Ph.D., Art Unit 1642, whose telephone number is (703)308-7553. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.

EXAMINER Julie E. Reeves, Ph.D.

JULIE REEVES
PATENT EXAMINES

Application No. 08/846 658

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.				
This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).				
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
7. Other: Sequences with in Spor without Eq. 10 Nor Sper not an CRF				
Applicant Must Provide:				
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.				
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
For questions regarding compliance to these requirements, please contact:				

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856